EdithAdaljisaPerezMD

PubMed

• Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conf...
  Hesham Elghazaly, Hamdy A Azim, Hope S Rugo, David Cameron, Sandra M Swain
  Cancer. 2024-10-01
• A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive...
  Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, Carlos L Arteaga, Ximing J Yang
  Breast Cancer Research and Treatment. 2024-09-01
• Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer.
  Saranya Chumsri, Tanmayi Pai, Yaohua Ma, Zhuo Li, Angelica Gil
  Journal of the National Comprehensive Cancer Network. 2024-08-26

Journal Articles

• Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer  
  Northfelt DW, Allred JB, Liu HS, Hobday TJ, Rodacker MW, Lyss AP, Fitch TR, Perez EA, Am J Clin Oncol, 4/1/2014
• Adjuvant exemestane with ovarian suppression in premenopausal breast cancer  
  Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA , Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr,..., N Engl J Med, 1/1/2014
• International study on inter-reader variability for circulating tumor cells in breast cancer  
  Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothe F, Metallo J, Rouas G, Payne RE, Coombes RC, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavro..., Breast Cancer Res, 1/1/2014
• Clinical Roundtable MonographNew Developments in Metastatic Breast Cancer:Integrating Recent Data into Clinical Practice  
  Perez EA, Rugo HS, Vahdat LT, Clin Adv Hematol Oncol, 10/1/2013
• How I Treat Patients with Advanced HER2-Positive Breast Cancer  
  Perez EA, How I Treat Patients with Advanced HER2-Positive Breast Cancer., 5/27/2013
• Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer  
  Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE, Sparano JA, J Clin Oncol, 7/1/2012
• Re: predictability of adjuvant trastuzumab benefit in n9831 patients using the ASCO/CAP HER2-positivity criteria response  
  Perez EA, Dueck AC, J Natl Cancer Inst, 6/1/2012
• Response Re: Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria  
  Perez EA, Dueck AC, J Natl Cancer Inst, 5/1/2012
• Reply to S Mahesh  
  Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA, J Clin Oncol, 1/1/2012
• Impact of race pace on development of hyponatremia in full- and half-marathoners  
  Maynard JR, Taylor WC III, McNeil RB, Shapiro SA, Mohseni MM, Vadeboncoeur TF, Silvers SM, Sumrall SV, Perez EA, Diehl NN, Impact of race pace on development of hyponatremia in full- and half-marathoners., 1/1/2012
• Commentary  
  Perez EA, Serene M, Frances C, Clin Adv Hematol Oncol, 1/1/2012
• Cardiotoxicity of Trastuzumab  
  Perez EA, Morgan JP, UpToDate, 1/1/2012
• Baselga J Pertuzumab improved PFS when given with trastuzumab, chemotherapy [Perspective editorial]  
  Perez EA, HemOnc TODAY, 12/1/2011
• New treatment strategies in the management of breast cancer  
  Perez EA, Eur J Cancer, 9/1/2011
• Clinical Roundtable Monograph: Recent Advances in the Treatment of Breast Cancer: Highlights From the 2010 San Antonio Breast Cancer Symposium  
  Perez EA, Burstein HJ, Hudis C, Clin Adv Hematol Oncol, 1/1/2011
• Evolving Paradigms for Optimizing Management of Breast CancerSymposium Report  
  Perez EA, Clinical Advances in Hematology and Oncology, 1/1/2011
• Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer  
  Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land..., Obstet Gynecol Surv, 11/1/2010
• What Your Patients Are Reading  
  Perez EA, The ASCO Post, 1/1/2010
• Compressing the timeline for cancer clinical trial activation  
  Doroshow JH, Hortobagyi G, Operational Efficiency Working Group of the Clinical Trials (Perez EA), Translational Research Advisory Committee, Natl Cancer Inst, 1/1/2010
• Reply to N Magne et Al  
  Halyard MY, Pisansky TM, Dueck AC, Suman VJ, Pierce LJ, Solin LJ, Marks LB, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez EA, J Clin Oncol, 12/1/2009
• Impact on cardiac toxicity with trastuzumab and radiotherapy: the question is still ongoing Reply to N Magne et al  
  Halyard MY, Pisansky TM, Dueck AC, Suman VJ, Pierce LJ, Solin LJ, Marks LB, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez EA, J Clin Oncol, 12/1/2009
• The Role of Targeted Therapy in Breast Cancer Treatment  
  Patel TJ, Perez EA, Coping, 9/1/2009
• HER2 Status Assessment: An Oncologist's Perspecitve  
  Perez EA, ASCO News & Forum, 4/1/2009
• A Practical Clinical Approach to Adjuvant Therapy in Breast Cancer - An Update  
  Hines SL, Tan WW, Moreno-Aspitia A, Roy V, Vallow LA, McLaughlin SA, Perez EA, US Oncol, 4/1/2009
• Reply to JM Guinebretiere and L Arnould et al  
  Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu M-Lm, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA, J Clin Oncol, 1/1/2009
• Join now to see all

Books/Book Chapters

• Expert Clinical Perspective: Controversies and Uncertainties in Diagnosis & Management of Cancer. 
  Chapter: Prevention and adjuvant therapy in breast cancer. 
  Page 523 - 531Gardner FP, Perez EAEditors: S. Abutalib.Wiley-Blackwell Health Sciences2014
• The CTSA Program at NIH: Opportunities for Advancing Clinical and Translational Research 
  Leshner AI, Terry SF, Axelrod S, Bond EA, Bonham AC, Curry SJ, Dennery PA, Horwitz RI, Kahn JP, Kelley RT, McCabe M, Perez EA, Rosen CJ.Editors: Leshner AI, Terry SF, Schultz AM, Liverman CT.The National Academies Press, Washington, DC2013
• Diseases of the breast. 
  Chapter: Side effects of systemic therapy: neurocognitive, cardiac, and secondary malignancies. 
  Page 692 - 704Moreno Aspitia A, Perez EAEditors: Harris JR; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PAEdition 4th,2010
• A National Cancer Clinical Trials System for the 21st Century 
  Mendelsohn J, Moses HL, Arbuck S, Berry D, Carducci MA, Dilts DM, Ellenberg SS, Fyfe G, Grubbs SS, Hricak H, Kaplan R, Liu MC, Newcomer LN, Perez EA, Sawyers CL, Schil...The National Academies Press, Washington, DC2010
• Management of breast diseases. 
  Chapter: Metastatic breast cancer. 
  Page 425 - 449Patel TA, Perez EAEditors: Jatoi I; Kaufmann M.Springer, Heidelberg; New York2010
• Principles and Practice of Surgical Oncology. 
  Chapter: Adjuvant Therapy in Breast Cancer. 
  Charles AJ, Roy V, Perez EA2009
• Pharmacology and therapeutics: principles to practice. 
  Chapter: Breast cancer. 
  Page 933 - 944Roy V, Perez EAEditors: Waldman SA, Terzic A.Saunders/Elsevier, Philadelphia, PA2009
• Diseases of the Breast 
  Chapter: Side Effects of Systemic Therapy: Neurocognitive, Cardiac, and Secondary Malignancies. 
  Page 692 - 704Moreno-Aspitia A, Perez EAEditors: Jay R. Harris, M.D.; Marc E. Lippman, M.D.; Monica Morrow, M.D.; C. Kent Osborne, M.D..Lippincott Williams & Willkins, Philadelphia, PAEdition 4th,2009
• Handbook of therapeutic antibodies. Volume 3. 
  Chapter: Bevacizumab (Avastin). 
  Page 779 - 812Diaz-Rubio E, Perez EA, Giaccone G2008
• 2007 Educational Book of the American Society of Clinical Oncology. 
  Chapter: Human Epidermal Growth Factor 2 - positive Breast Cancer: Treatment of Metastatic Disease - from Bench to Bedside. 
  Page 90 - 94Amar S, Perez EA2007
• Breast cancer: Translational therapeutic strategies. 
  Chapter: HER2-Positive Breast Cancer: Current Treatment Strategies. 
  Page 189 - 202Perez EA, Baweja MEditors: Gary H. Lyman & Harold J. Burstein.Taylor & Francis Publishing Company2007
• Textbook of Breast Cancer: A Clinical Guide to Therapy 
  Chapter: Conventional adjuvant chemotherapy: Where are we 30 years later? 
  Page 225 - 239Perez EAEditors: Bondadonna G, Hortobagyi GN, Valagussa P.London & New York, London & New YorkEdition 3rd,2006
• Breast cancer and molecular medicine. 
  Chapter: Molecular profiling in breast cancer. 
  Page 977 - 1006Perez EA, Enui AEEditors: Piccart MJ, et al.Springer, Berlin2006
• Oncology news international cancer management: a multidisciplinary approach. 
  Chapter: Aromatase inhibitors as adjuvant therapy for breast cancer. 
  Page 31 - 54Perez EASt. Louis, MO2005
• ASCO 2005 Educational Book, 41st Annual Meeting Orlando, FL 2005. 
  Chapter: Aromatase inhibitors and bone health. 
  Page 27 - 34Mincey BA, Perez EA2005
• American Society of Clinical Oncology. American Society of Clinical Oncology 2004 Educational Book. 
  Chapter: Beyond chemotherapy: incorporation of targeted agents for adjuvant treatment of breast cancer. 
  Page 23 - 27Perez EAASCO, Alexandria, VA2004
• Manual of Breast Diseases. 
  Chapter: Metastatic breast cancer. 
  Page 365 - 387Perez EA, Russell CAEditors: Jatoi I.Lippincott Williams & Willkins, Philadelphia, PA2002
• (TeleLecture: Clinics in Oncology). J of Oncology: Index & Reviews. 
  Chapter: Role of Trastuzumab in breast cancer. 
  Page 10 - 12Perez EA2000
• Mit Taxol in der Therapie solider Tumeron ins nachste Jahrtausend. 
  Chapter: Antiemetic therapy with granisetron with and without corticosteroids and NK-1 inhibitors. 
  Page 156 - 161Perez EAAktuelle Onkologie1999
•  
  Chapter: Taxol (paclitaxel) injection and doxorubicin combination chemotherapy: considerations regarding cardiotoxicity issues. 
  Perez EABristol-Myers Squibb Company, Princeton, NJ1997
• Conn's current therapy 1997. 
  Chapter: Nausea and vomiting. 
  Page 4 - 9Perez EA, Hallstone AEEditors: Nausea and vomiting..W. B. Saunders Company, Philadelphia, PA1997
• Supportive care of the cancer patient. 
  Chapter: Improved control of chemotherapy-induced emesis. 
  Page 121 - 139Perez EAEditors: Sweetenham JW, Williams C.Arnold, London1997
• Cecil textbook of medicine. 
  Chapter: Molecular mechanisms of drug resistance. 
  Page 1056 - 1060DeGregorio MW, Perez EAEditors: Bennett JC, Plum F.W. B. Saunders Company, Philadelphia, PAEdition 20th,1996
•  
  Chapter: Taxol: clinical experience in the outpatient setting. 
  Page 36 - 40Aisner J, Albain K, Belani C, Bunn P, Choy H, Glantz M, Greco F, Green M, Ozols R, Perez EABristol Myers Printing, Evansville, IN1994
• Satellite Symposium. European Society of Medical Oncology (ESMO) 
  Chapter: Acute emesis: can oral treatment match IV? 
  Page 18 - 25Perez EA1994
• Join now to see all

Abstracts/Posters

• Targeting hsp90 in breast cancer: ENCHANT-1 (nct01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic HER2-positive o...
  Cameron D, Spector N, Gomez H, Hickish T, Vandat L, Kim SB, Sheldon E, El-Hariry I, Perez EA, Awada A, Eur J Cancer, 3/1/2014
• Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic bre...
  Perez EA, Lopez-Vega JM, Petit T, Zamagni C, Freudensprung U, Bastiere-Truchot L, Walker R, Andersson M, Eur J Cancer, 3/1/2014
• Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
  Adams S, Gray R, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA, Badve SS, Cancer Res, 12/1/2013
• A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer...
  Awada A, Kaufman PA, Yelle L, Cortes J, Wanders J, O’Shaughnessy J, Olivo MS, He Y, Garzon F, Dutcus CE, Binder TA, Twelves C, Perez EA, Cancer Res, 12/1/2013
• The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 ...
  Awada A, Spector N, El-Hariry I, Rodriguez AA, Erban JK, Cortes J, Gomez H, Kong A, Hickish T, Fein L, Vahdat L, MacPherson I, Canon J-L, Mansoor S, Giovanne A, McAdam..., Cancer Res, 12/1/2013
• Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301.
  Kaufman PA, Yelle L, Cortes J, Perez EA, Awada A, Wanders J, Olivo MS, He Y, Dutcus CE, Twelves C, Cancer Res, 12/1/2013
• The prognosis of small HER2+ breast cancers: A meta-analysis of the randomized trastuzumab trials.
  O’Sullivan CC, Holmes E, Spielman M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, de Azambuja E, Piccart-Gebhart M, Zujewski JA, ..., Cancer Res, 12/1/2013
• Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer.
  Perez EA, Lopez-Vega JM, Del Mastro L, Petit T, Zamagni C, Freudensprung U, Bastiere-Truchot L, Walker R, Andersson M, Cancer Res, 12/1/2013
• EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial.
  Rimm DL, Holmes E, Schalper K, Bradbury I, Zarrella E, Ellis C, Baselga J, Eidtmann H, Piccart M, Harbeck N, Pusztai L, Perez EA, Cancer Res, 12/1/2013
• Limits of [18F]-FLT PET as a clinical biomarker of proliferation in breast cancer.
  Schmidt EV, Blackman S, Iannone R, Senderak ET, Railkar RA, Evelhoch PD, Mozley PD, Perez EA, McDonough M, Rimawi M, Tolaney S, Kim S-B, Chung H-C, Cancer Res, 12/1/2013
• Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribuli...
  Cortes J, Awada A, Kaufmann PA, Yelle L, Perez EA, Velikova G, Wanders J, Olivo M, He Y, Ductus C, Simons R, Bischoff J, Twelves C, Onkologie, 10/1/2013
• A phase Ill, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treat...
  Kaufmann PA, Cortes J, Awada A, Yelle L, Perez EA, Wanders J, Olivo M, He Y, Ductus C, Bischoff J, Twelves C, Onkologie, 10/1/2013
• New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with mbc treated with eribulin or capecitabine in ...
  Perez EA, O'Shaughnessy J, Twelves C, Cortes J, Awada A, Yelle L, Wanders J, Olivo M, He Y, Kaufman PA, Eur J Cancer, 9/1/2013
• Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): results from an expanded access study.
  Yardley DA, Krop IE, LoRusso P, Robert NJ, Mayer M, Abidoye OO, Lai C, Yoo B, Perez EA, J Clin Oncol, 9/1/2013
• The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2...
  Awada A, Rodriguez AA, Kong A, Erban JK, Cortes J, Mano MS, Perez EA, El Hariry I, Vukovic VM, Teofilovici F, Yalcin I, Bradley R, Cameron DA, J Clin Oncol, 5/1/2013
• Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studie...
  Clynes R, Knutson KL, Ballman KV, Erskine CL, Norton N, Sumrall SV, Northfelt DW, Tan W, Calfa CJ, Pegram MD, Perez EA, J Clin Oncol, 5/1/2013
• Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribuli...
  Cortes J, Awada A, Kaufman PA, Yelle L, Perez EA, Velikova G, Wanders J, Olivo MS, He Y, Dutcus C, Simons WR, Twelves C, J Clin Oncol, 5/1/2013
• Crozier JA, Necela BM, Thompson EA, Geiger X, Moreno-Aspitia A, McCullough AE, Pockaj BA, Cunliffe H, Sun Z, Kalari KR, Kachergus JM, O'Shannessy DJ, Maltzman JD, Ball..., J Clin Oncol, 5/1/2013
• Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patie...
  Hoch U, Fry DG, Chia YL, Caygill K, Hannah AL, Perez EA, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Rugo HS, Im SA, Xu B, Anderes KL, Davis DW, J Clin Oncol, 5/1/2013
• A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treat...
  Kaufman PA, Cortes J, Awada A, Yelle L, Perez EA, Wanders J, Olivo MS, He Y, Dutcus C, Twelves C, J Clin Oncol, 5/1/2013
• Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study...
  Knutson KL, Perez EA, Ballman KV, Erskine CL, Fox N, McCarl CA, Norton N, Sumrall SV, Northfelt DW, Tan W, Calfa CJ, Pegram MD, Clynes R, J Clin Oncol, 5/1/2013
• Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative b...
  Moreno-Aspitia A, Liu H, Hillman DW, Rowland KM, Geiger X, Stella PJ, Kourlas P, Gross HM, Karlin NJ, Bury MJ, Soori GS, Nassar A, Perez EA, Alliance for. N0937 (Allia..., J Clin Oncol, 5/1/2013
• The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831.
  Perez EA, Butler SM, Dueck AC, Baehner FL, Jamshidian F, Cherbavaz DB, Thompson EA, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV, J Clin Oncol, 5/1/2013
• Biomarker testing methods in breast, gastric, and lung cancers: A benchmarking survey of NCI cancer centers.
  Schink JC, Trosman JR, Weldon CB, Siziopikou KP, Gradishar WJ, Tsongalis GJ, Patel JD, Benson AB, Perez EA, J Clin Oncol, 5/1/2013
• Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes:...
  Shulman LN, Berry D, Cirrincione CT, Becker H, Perez EA, O'Regan R, Martino S, Shapiro CL, Atkins J, Schneider C, Kimmick GG, Burstein HJ, Norton L, Muss HB, Hudis C, ..., J Clin Oncol, 5/1/2013
• Join now to see all

Lectures

• Updates on Metastatic Breast Cancer: HER2+ 
  Amelia Island, FL - 1/1/2014
• State of the Art Anti-HER2 Therapies for Breast Cancer 
  Dublin, Ireland - 1/1/2014
• Gene Profiling for Early Stage Breast Cancer: What is Clinically Relevant? 
  Kona, HI - 1/1/2014
• Sixteen years of Targeted HER2+ Therapy in Breast Cancer 
  London, United Kingdom - 1/1/2014
• Neoadjuvant and Adjuvant Hormonal Manipulation in Early Stage Breast Cancer 
  New Orleans, LA - 1/1/2014
• Metastatic Breast Cancer: Now and the Future 
  Paris, France - 1/1/2014
• Breast Cancer: New Advances in Breast Cancer Management 
  Wichita, KS - 1/1/2014
• Advances in Management of Metastatic HER2+ BC 
  Amelia Island, FL - 1/1/2013
• Approach to HER2+ Mets Breast Cancer: the Newest and Greatest and the Real World 
  Kuala Lumpur, Malaysia - 1/1/2013
• Breast Cancer Treatment-State of the Art Now and for the Future: What is the Next Best Thing? 
  Kuala Lumpur, Malaysia - 1/1/2013
• Opportunities and Barriers to Personalized Medicine 
  Kuala Lumpur, Malaysia - 1/1/2013
• New Treatments in Breast Cancer 
  Paris, France - 1/1/2013
• Personalized Medicine in Breast Cancer 
  Paris, France - 1/1/2013
• The Conquest of Cancer and the Next Generation of Cancer Researchers 
  Washington, DC - 1/1/2013
• Individualized Management of Breast Cancer: A Post San Antonio Meeting Update 
  Mayo School of Continuous Professional Development, Jacksonville, Florida - 2/11/2012
• Comparison of fusion detection in RNA-SEQ and Mate-Pair DNA Seq Data. 
  Marco Island, FL - 1/1/2012
• Impact of Adjuvant Trastuzumab on Local Regional Recurrence: Data from the NCCTG N9831 Study. 
  San Antonio, TX - 1/1/2012
• Molecular Diagnosis - the US Experience 
  Sao Paulo, Brazil - 1/1/2012
• Generally Accepted Standards for Clinical Trial Approval 
  Sao Paulo, Brazil - 1/1/2012
• International Considerations for Multi-site Trials 
  Sao Paulo, Brazil - 1/1/2012
• International Insurance Requirements for Patients 
  Sao Paulo, Brazil - 1/1/2012
• Safety and Surveillance Reporting for Adverse Events, Coding, etc. 
  Sao Paulo, Brazil - 1/1/2012
• New Updates on Adjuvant Chemotherapy in Breast Cancer 
  Shanghai, China - 1/1/2012
• Current Treatment of HER2+ Disease Including Latest Combinations 
  Argentina - 1/1/2011
• State of the Art: Anti-HER2 Therapy for Breast Cancer 
  Cairo, Egypt - 1/1/2011
• Join now to see all

Other

• ALTTO Trials Findings For Treating HER2+ Breast Cancer - Mayo Clinic. 
  Perez EA, Mayo Clinic
  6/1/2014
• Dr. Perez on a Genomic Analysis of the NCCTG N9831 Adjuvant Trastuzumab Trial. 
  Perez EA, OncLive
  6/1/2014
• The Race Against Breast Cancer: What Mayo Clinic Has Learned So Far. 
  Perez EA, Thompson EA, Mayo Clinic
  2/1/2014
• Metastatic Breast Cancer Treatment Challenges. 
  Brufsky AM, Hurvitz S, O'Shaughnessy J, Perez EA, Rugo HS, Seidman AD, OncLive Peer Exchange
  6/1/2013
• Edith A. Perez, MD: Anti-HER2 Therapies. 
  Perez EA, The Group Room
  3/1/2013
• Dr. Edith Perez on Study 301 That Compared Eribulin to Capecitabine in MBC. 
  Perez EA, Targeted Oncology
  2/1/2013
• Dr. Perez on the Antibody-Drug Conjugate T-DM1. 
  Perez EA, OncLive
  2/1/2013
• Dr. Perez on the Phase III Eribulin/Capecitabine Study. 
  Perez EA, OncLive
  1/1/2013
• Dr. Perez on the Adjuvant Treatment of Breast Cancer. 
  Perez EA, OncLive
  1/1/2013
• Dr. Edith Perez Discusses Anti-HER2 Therapies - 2012 SABCS. 
  Perez EA, Breast Cancer Answers
  12/1/2012
• Dr. Perez on Patient Selection for Adjuvant Chemotherapy. 
  Perez EA, OncLive
  3/1/2012
• Dr. Perez Discusses Optimizing Adjuvant Therapy. 
  Perez EA, OncLive
  2/1/2012
• Dr. Perez Describes Retesting Recurrent Breast Cancer. 
  Perez EA, OncLive
  2/1/2012
• Dr.Perez Discusses Obesity as a Predictive Marker. 
  Perez EA, OncLive
  1/1/2012
• Dr. Perez Discusses the BOLERO-2 Everolimus Trial. 
  Perez EA, OncLive
  12/1/2011
• Dr. Perez Discusses the B-34 Clodronate Study. 
  Perez EA, OncLive
  12/1/2011
• Dr. Edith Perez Discusses Her Ongoing Research. 
  Perez EA, OncLive
  4/1/2011
• Dr. Perez on her Anticipated Results for ASCO and SABCS. 
  Perez EA, OncLive
  1/1/2011
• 2010 SABCS Interview with Edith A. Perez, M.D. 
  Perez EA, American Association for Cancer Research
  12/1/2010
• Adjuvant treatment options for early stage HER2-positive breast cancer: Where are we now? 
  Perez EA, PeerView in Review
  1/1/2006
• Weekly paclitaxel, carboplatin, and trastuzumab shows better efficacy and lower toxicity for the treatment of HER2-positive metastatic breast cancer compared with dosi... 
  Perez EA, PeerView in Session direct from 26th San Antonio Breast Cancer Symposium (SABCS)
  1/1/2003
• Audioforum on chemotherapy-induced nausea and vomiting. 
  Perez EA, Scientific Exchange Inc, Greenwich, CT
  1/1/1997
• Screening for breast cancer: methods and controversies. 
  Perez EA, PrimePractice
  1/1/1996
• Tamoxifen and endometrial cancer: making sense of the studies. 
  Perez EA, PrimePractice
  1/1/1996
• Cardiotoxicity of trastuzumab 
  Perez EA, Morgan JP
  http://www.uptodate.com/contents/cardiotoxicity-of-trastuzumab
  UpToDate, Wolters Kluwer Health - 2013-02-11
• Join now to see all